BACKGROUND:
Children with acute lymphoblastic leukemia (ALL) have increased risk for obesity and short stature. Data on patients treated on contemporary protocols without cranial irradiation are limited.
METHODS:
Changes in body mass index (BMI), height, and weight Z-scores from diagnosis to 5 years off therapy were evaluated with multivariable analysis in 372 children with ALL (aged 2–18 years at diagnosis) enrolled on the St. Jude Total XV protocol in 2000–2007.
RESULTS:
The percentage of overweight/obese patients increased from 25.5% at diagnosis to approximately 50% during the off-therapy period. Median BMI Z-scores increased significantly during glucocorticoid therapy (induction [Δ0.56; P<0.001, 95% confidence interval [CI]: 0.29–0.64] and re-induction II [Δ0.22; P=0.001, 95% CI: 0.13–0.49]) and during the first year post-therapy (Δ0.18; P=0.006, 95% CI: 0.08–0.46). Among patients who were of healthy weight/underweight at diagnosis, those aged 2 to <10 years at diagnosis had a significantly higher risk of becoming overweight/obese during or after therapy than did those aged ≥10 years (P=0.001). Height Z-scores declined during treatment and improved post-therapy. Age 2 to <10 years at diagnosis, low-risk status, white blood cell count (WBC) < 50×109/L at diagnosis, and negative central nervous system (CNS) disease were associated with significantly better improvement in height Z-scores during the off-therapy period than were age ≥10 years, standard/high-risk status, WBC ≥ 50×109/L, and positive CNS disease, respectively.
CONCLUSIONS:
Obesity was prevalent, and height growth, especially in patients with identified risk factors, was compromised. Multidisciplinary intervention should begin during induction therapy and continue during the off-therapy period.